Cargando…

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines

Detalles Bibliográficos
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077128/

Ejemplares similares

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Topoisomerase II isoforms are required for HIV-1 reverse transcription
por: Sunnam, Lokeswara Balakrishna, et al.
Publicado: (2012)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes.
por: Coutts, J., et al.
Publicado: (1993)

The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
por: Turley, H., et al.
Publicado: (1997)

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β
por: Zhou, Z, et al.
Publicado: (2001)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

The α isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells
por: Farr, Christine J., et al.
Publicado: (2014)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

The Significance of Topoisomerase II Alpha in Invasive Breast Carcinoma
por: Arthi, M, et al.
Publicado: (2021)

Localization of topoisomerase II in mitotic chromosomes
Publicado: (1985)

Topoisomerase II has to work late
por: Leslie, Mitch
Publicado: (2014)

Diversity and Functions of Type II Topoisomerases
por: Sutormin, D. A., et al.
Publicado: (2021)

Chromatinization Modulates Topoisomerase II Processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

Chromatinization modulates topoisomerase II processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

Mitotic chromosomes are constrained by topoisomerase II–sensitive DNA entanglements
por: Kawamura, Ryo, et al.
Publicado: (2010)

Natural Products as Topoisomerase II Poisons: Effects of Thymoquinone on DNA Cleavage Mediated by Human Topoisomerase IIα
por: Ashley, Rachel E., et al.
Publicado: (2014)

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.
por: Sandri, M. I., et al.
Publicado: (1996)

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer
por: MacGrogan, G, et al.
Publicado: (2003)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a(-/- )mutants
por: Sapetto-Rebow, Beata, et al.
Publicado: (2011)

C-Terminal regions of topoisomerase IIα and IIβ determine isoform-specific functioning of the enzymes in vivo
por: Linka, René M., et al.
Publicado: (2007)

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
por: Davies, S. L., et al.
Publicado: (1997)

An RNase-sensitive particle containing Drosophila melanogaster DNA topoisomerase II
Publicado: (1994)

Developmental regulation of Drosophila DNA topoisomerase II
Publicado: (1991)

The Roles of DNA Topoisomerase IIβ in Transcription
por: Madabhushi, Ram
Publicado: (2018)

Targeting DNA Topoisomerase II in Antifungal Chemotherapy
por: Kondaka, Kavya, et al.
Publicado: (2022)

Topoisomerase II expression as a determinant of chromosomal radiosensitivity and possible susceptibility in breast cancer
por: Bryant, PE, et al.
Publicado: (2008)

Topoisomerase II inhibition involves characteristic chromosomal expression patterns
por: Reymann, Susanne, et al.
Publicado: (2008)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors
por: Miura, Yosuke, et al.
Publicado: (2017)

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
por: Deng, Shiwei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2cmqggu07m4p9868cdnlv39sgu